
About
Axcelead Drug Discovery Partners, Inc. provides drug discovery and development services for biotechnology and pharmaceutical partners, with work spanning target discovery through IND enabling. It is based in Fujisawa, Kanagawa, Japan and was formed in 2017 as a Takeda spin-out.
Services
Integrated drug discovery
End-to-end drug discovery services from target discovery to IND-enabling translational research.
Axcelead Booster
Data-driven drug candidate generation using legacy pharma projects, proprietary data, AI tools, and discovery platforms.
Target identification / validation
Supports identification of novel drug targets using human data-driven transcriptomics and proteomics, and validates targets with human samples and disease models.
Hit identification / characterization
Provides HTS strategy design, assay development, hit characterization, compound library screening, and hit prioritization.
Lead generation / optimization
Supports medicinal and analytical chemistry, biology, DMPK, safety evaluation, and in silico design for lead generation and optimization.
Candidate selection
Evaluates optimized compounds for IND feasibility using PK/PD/E, TK/TD, modeling and simulation, human PK/effective dose prediction, and safety assessment.
ADME, DMPK & toxicology
IND enabling
Provides Smart-IND project support from candidate selection to IND filing, including strategy, project management, non-GMP bulk preparation, and modality-specific planning.
ADME, DMPK & toxicology
Chemistry
Offers medicinal, computational, synthetic, and analytical chemistry, including hit expansion, lead generation, and lead optimization.
6 more services
- Targeted protein degradation
- RNA-targeted small molecules
- Omics
- Bioinformatics
- In Vitro/In Vivo Pharmacology
- Genetically Modified Animal
- Lead time
- 2 days to 12 months
- 1 year
- What to send
- Diseases of interest, target classes, or specific targets
- Organization / Company
Capabilities
- Processes
- Small molecule
- Peptide
- Oligonucleotide
- Cell therapy
- HTS
- In vivo
- Capacity
- 1.2+ million compounds
- 1,000 pharma-originated legacy projects
- 700+ HTS experiences
- 96 parallel syntheses over 5 to 10 days
- More than 50 projects for 5 years
- 7 candidates
3 more
- 1 IND
- About 240 employees
- 1.5 million compounds
Equipment
- High throughput screening
- GPU machines
- 2000 CPU cluster machines
Industries served
- Biotech
- Pharmaceuticals
- Academia
- Public institutions
Company
- Type
- CRO
- Founded
- 2017
- Team
- About 240
Locations
- Based in
- Kanagawa, Japan
- Sites
- Fujisawa, Japan
- Fujisawa, Kanagawa, Japan
- Serves
- Biotechnology and pharmaceutical partners, corporate, start-up, academia, and public institutions, Japan, around the world